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Abstract
Over the past few years the systematic investigation of paired helical filament assembly from tau protein in vitro has
become feasible. We review our current understanding of the structure and conformations of tau protein and how this affects
tau’s assembly into the pathological paired helical filaments in Alzheimer’s disease. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Alzheimer’s disease (AD) is accompanied by a
number of structural and metabolic alterations in
the brain. Two characteristic hallmarks are the pro-
tein aggregates in amyloid plaques (made up mostly
of the AL peptide, a derivative of the membrane
protein APP) and in the neuro¢brillary tangles (con-
sisting largely of the microtubule-associated protein
tau). Certain forms of AD are related to mutations
in the APP gene or the presenilin genes PS1 and PS2
(reviews: [1,2]) so that much of current Alzheimer
research is aimed at clarifying the chain of events
that lead from the altered gene to the aggregated
gene product. Recently in several Alzheimer-related
dementias, now summarized as FTDP-17 (fronto-
temporal dementia with Parkinsonism linked to
chromosome 17), mutations in the tau gene have
been described ([3^7], review: [8]). However, the
mechanism for these tau pathologies is still un-
known.
In contrast to amyloid plaques the distribution of
neuro¢brillary deposits correlates well with the clin-
ical progression of the disease [9,10] and thus can be
used to subdivide the disease into six stages [9,11]. In
this regard, tau deposits have a comparable diagnos-
tic value to the loss of synapses [12,13]. In addition
the level of tau in the cerebrospinal £uid becomes
elevated in AD which opens up a potential route to
early diagnosis [14^16].
Tau is a mainly but not exclusively neuronal mi-
crotubule-associated protein (MAP). One of its func-
tions is the stabilization of axonal microtubules [17] ;
other functions include a role in signal transduction
[18,19], interaction with the actin cytoskeleton [20],
neurite outgrowth [21^23], interactions with the plas-
ma membrane [24,25], anchoring of enzymes such as
protein kinases and phosphatases [26^29], and the
regulation of intracellular vesicle transport ([30]; re-
viewed in [31,32]). Since tau is a highly soluble pro-
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tein, and survives heat, denaturing agents or acid
treatment without losing its biological function (the
binding to microtubules and the stimulation of their
assembly [33,34]), it is counterintuitive that this pro-
tein should aggregate into insoluble ¢bers. Over the
past years a number of studies on the structure and
assembly of tau, its phosphorylation by various ki-
nases, and its interaction with microtubules have
been carried out. Phosphorylation tends to dissociate
tau from its natural partner, the microtubule [35^43].
Since this increases the soluble pool of tau it might
be an important ¢rst step in generating protein for
the assembly of paired helical ¢laments (PHFs).
However, the assembly itself appears to depend
mainly on other factors (conformation, oxidation,
nucleation by other components, see below). In the
following we will focus on the question of tau and
PHF structure, and the mechanism of ¢lament for-
mation.
2. Structure and conformations of soluble tau
In the human central nervous system the tau gene
(location on chromosome 17q21) contains 15 exons
with the major tau protein isoform being encoded by
11 exons [44]. By alternative splicing of exons 2, 3
and 10 six main isoforms of tau with 352^441 amino
acid residues are produced [45^47] (Fig. 1). There are
either no, one, or two inserts of 29 residues each near
the N-terminus (exons 2 and 3), and three or four
homologous stretches of 31 or 32 amino acid resi-
dues each, the ‘repeats’ in the C-terminal half (repeat
R2 encoded by exon 10 may be missing). Thus the
longest isoform in the CNS has four repeats and two
insert 441 residues, the shortest (fetal) isoform 352
residues has three repeats and no inserts. A ‘big tau’
isoform containing V300 additional residues (exon
4a) is expressed in peripheral nerves [48,49]. Tau con-
tains either one or two cysteine residues, Cys291 in
repeat 2 (present only in four-repeat isoforms and
Cys322 in repeat 3 (always present). This di¡erence
has an in£uence on in vitro PHF assembly (see be-
low) and the balance between isoforms may be im-
portant within the adult brain. The amino acid com-
position of tau is dominated by hydrophilic and
charged residues, an acidic stretch near the N-termi-
nus followed by mostly basic domains. The repeat
region is £anked upstream by a basic proline-rich
region (about 25% proline) and downstream by an-
other basic stretch also containing several prolines.
Many of these occur in Ser-Pro or Thr-Pro motifs
whose phosphorylation is diagnostic of Alzheimer
tau. The C-terminal half of tau (repeats plus £anking
regions) constitutes the microtubule binding domain
[50^52].
Fig. 1. Bar diagram of tau protein, showing the domains and isoforms generated by alternative splicing. The microtubule binding do-
main consists of repeats R1^R4 and the £anking regions P (P1, P2, proline-rich, dark shade). Alternatively spliced exons are indicated
above (black bars); exon 4a is present in the ‘big tau’ isoform of peripheral nerves. Exons E2 (insert 1, I1), E3 (insert 2, I2), and E10
(repeat 2, R2) may be absent due to alternative splicing, generating the six isoforms in human CNS. A number of potential phosphor-
ylation sites reported in the literature are listed above the bar, and mutations occurring in FTDP-17 below.
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Tau has resisted all e¡orts at crystallization so far
(precluding an X-ray crystallographic analysis), and
it is too large for a structural analysis by magnetic
resonance methods. Therefore, details of the folding
of the polypeptide chain are unknown. Most of the
available structural data come from electron micros-
copy, spectroscopy, or small angle X-ray scattering
of tau in solution [33,53^57]. Additional information
comes from hydrodynamic measurements showing
that the polypeptide chain has a highly asymmetric
shape (axial ratio of s 10 [58]). In summary, these
data argue for a natively unfolded conformation of
tau with little K-helix and L-sheet [55,56]. This loose,
open structure may explain why tau is resistant to
heat, denaturants, or acids, because these treatments
destroy the compact folding of other proteins but
cannot harm tau. These experimental data are corro-
borated by various secondary structure prediction
methods which yield little K and L structure (less
than 10% [59]).
Antibodies provide another tool to assess the pro-
tein folding if their epitopes are formed from non-
contiguous parts of the chain which must come to-
gether in space. One example is SMI34, originally
raised against phosphorylated neuro¢laments [60]
which cross-reacts with Alzheimer tau and requires
the repeats plus either of the £anking regions in
phosphorylated form [61]. Another case is that of
the antibodies Alz50 and MC-1 which recognize a
conformation of tau typical of AD-tau, are inde-
pendent of phosphorylation but require regions
both near the N-terminus and in the repeats for their
epitopes [62,63]. It is remarkable that the three anti-
bodies against ‘pathological’ tau recognize a folded
conformation which brings regions outside the re-
peats into close vicinity of the repeats, and it is likely
that this folding is important for the assembly of tau
into PHFs. In this context it is interesting to note
that Pin1, a prolyl-peptide isomerase important in
mitosis, can interact with tau protein phosphorylated
at Thr231 (followed by Pro232). This reverts the con-
formation that is incompetent to bind to microtu-
bules into a competent one, probably by prolyl-pep-
tide isomerization [64]. Since the proline-rich region
of tau contains several Ser/Thr-Pro motifs which are
phosphorylated in AD, it will be important to know
their in£uence on the conformation of tau and how
such conformational changes are regulated. That tau
can indeed adopt distinct conformations has been
observed in sequential phosphorylation reactions
where the AD-speci¢c phosphoepitope of antibody
AT-100 in the proline-rich region can only be gener-
ated by a sequential phosphorylation of tau ¢rst by
GSK-3L (at Thr212) and then by PKA (at Ser214),
indicating that pre-phosphorylation at certain sites
(e.g. Ser214) can alter the conformation such that
other phosphorylation reactions are no longer possi-
ble [39].
Dimeric tau derives its importance from the fact
that it is a key intermediate in the assembly of PHFs
[55,65]. Covalently linked dimers can be formed by
disul¢de cross-linking, they are therefore not ob-
served in reducing conditions and not expected in
healthy nerve cells as long as they maintain their
reducing potential. In the electron microscope, tau
dimers are seen as rod-like particles (length 25^35
nm, depending on the tau construct [55]), similar to
the monomers. Antibody labeling and rotary shad-
owing electron microscopy suggest that the two
monomers of the dimer are arranged in an antipar-
allel fashion [55]. However, this shape may be over-
simpli¢ed by the technique used, since in solution the
dimers also adopt a mostly random structure like
monomers, as judged by circular dichroism spectros-
copy [65]. Since three-repeat tau contains only one
cysteine residue (Cys322 in R3) only dimers can be
formed upon oxidation. The situation is more com-
plicated for four-repeat tau, which bears two cysteine
residues (Cys291 in R2 and Cys322 in R3) and can
form various dimeric forms and an internal disul¢de
bridge.
3. Structure of paired helical ¢laments
3.1. Ultrastructural morphology
The name of PHFs is derived from their electron
microscopic appearance as two strands (Fig. 2). They
are twisted around one another, such that the cross-
over repeats are around 75^80 nm and their apparent
width varies between 10 and 22 nm, as if each strand
had a diameter of about 10 nm [54]. A fraction of
PHFs isolated from Alzheimer brains (about 5%) are
not twisted but straight, as if the two proto¢brils ran
parallel to each other [53]. Other variants of tau ¢l-
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aments are observed in certain familial dementias,
showing twisted ribbon-like ¢laments with an irreg-
ular periodicity of 90^130 nm, e.g. in MSDT [66],
familial progressive subcortical gliosis [67] or cortico-
basal degeneration [68]. Image reconstructions sug-
gest that both appearances can be explained by a
similar domain structure of the proto¢brils [53].
The PHFs usually terminate in an abrupt fashion
without fraying out, suggesting that the two strands
are not separate entities on a molecular level. This
would be explained if the constituent subunits of tau
protein were distributed over both sub¢bers. Images
from atomic force scanning microscopy emphasize a
ribbon-like structure, twisting with the same cross-
over distance of V80 nm, but without the subdivi-
sion into two strands [69]. The main problem in all
models of PHFs thus far is that their protein sub-
units cannot be clearly delineated so that the packing
of molecules is still unknown.
3.2. Biochemical composition
It is widely accepted that all six tau isoforms occur
in PHFs [70,71] while other tangle proteins are only
peripherally associated (e.g. ubiquitin [72]). However,
the situation of isoform composition can be di¡erent
in other dementias with tau pathology where four-
repeat isoforms predominate (e.g. FTPP-17 [6,73]) or
three-repeat isoforms (e.g. Pick’s disease [74]). The
tau protein which is found in ¢laments is hyperphos-
phorylated [61,75^78]. Important constraints for
structural models of tau ¢laments come from proteo-
lytic cleavage and antibody labeling experiments,
suggesting that the structural core of PHFs contains
the equivalent of three repeats [79]. The remainder of
tau (both N- and C-terminus) forms the ‘fuzzy coat’
and can be removed by proteases such as pronase
[80^82].
A feature of many amyloid deposits is that the
protein ¢brils are enriched in L-sheet content [83].
The L strands usually run perpendicular to the helix
axis forming a ‘cross-L’ motif [57,84]. Such ¢bers can
be stained with certain dyes such as Congo red or
thio£avine S which are thought to interact with the
repeating L strands [85]. Since PHFs react with these
dyes to some extent (see below) it had been assumed
that PHFs had a cross-L structure of subunits. Re-
peated L strands should reveal an axial periodicity of
about 0.47 nm by X-ray di¡raction which was re-
ported in one case [57] but could not con¢rmed in
other studies [56]. Similarly they should generate a
maximum around 1620^1630 cm31 in a Fourier
transform infrared (FTIR) spectrum, in contrast to
the observed maximum at 1658 cm31 which is typical
of a low content of L structure [65]. Thus the data
obtained from X-ray di¡raction for PHFs could not
be con¢rmed by FTIR spectroscopy [56]. An explan-
ation of these inconsistencies could be the di⁄culty
of preparing PHFs from brain tissue without any
impurities and the high sensitivity of X-ray di¡rac-
tion to any regular structure. However, the results
from X-ray di¡raction and FTIR spectroscopy do
Fig. 2. Electron micrographs of paired helical ¢laments assembled in vitro. (left) Htau23 (the smallest, fetal isoform) assembled in the
presence of the polyanionic cofactor heparin. (right) K19 (a construct comprising repeats R1, R3, and R4) assembled in the presence
of poly-Glu. Note the double-stranded twisted appearance with a cross-over repeat of V80 nm indicated by arrows.
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not indicate an extended L-sheet structure. These re-
sults are consistent with the near-absence of second-
ary structure with full-length tau in solution noted
above (but do not exclude the possibility of a local L
structure in PHFs which would be below detectabil-
ity by spectroscopic methods, see ¢nal Note).
4. Assembly of tau into PHFs in vitro
4.1. The repeat region of tau is necessary and
su⁄cient for PHF assembly
Tau aggregates have been observed in the brains of
patients a¡ected with AD and related tauopathies,
but so far no tau ¢laments have been observed in
any model systems such as cells transfected with
tau or transgenic mice. Therefore our knowledge
about the mechanism of tau assembly into PHFs
stems largely from in vitro data. To understand the
principles it is necessary to assemble the subunits
into the ¢bers in vitro and study the structure both
in the subunit and in the polymeric states. For PHFs
the progress has been slow, primarily because tau is
soluble in most circumstances. Many peptides have a
tendency to aggregate in certain conditions, but the
signi¢cance remains unclear if the aggregates do not
resemble the native ¢ber (for examples see [86]).
Thus, tau isolated from brain tissue can form ¢bers
of homogeneous diameter [87,88], but the relation-
ship to PHFs remains unclear. Tau can also form
¢laments in some reducing conditions and in the
presence of free fatty acids, but these do not show
the typical paired helical ¢lament appearance [89,90].
Bona ¢de PHFs, showing the appropriate diameter
and periodicity, were ¢rst assembled from recombi-
nant tau constructs containing essentially the repeats
[55], albeit at low e⁄ciency. Assembly was strongly
promoted by the covalent dimerization of tau via
Cys322, whereas site-directed mutagenesis of
Cys322 to alanine inhibited PHF assembly [65].
Three-repeat tau constructs, having one cysteine,
can be dimerized by oxidation and form PHFs read-
ily, while four-repeat constructs tend to form intra-
molecular cross-bridges and do not readily dimerize
and assemble. Nevertheless, even with dimerized
three-repeat constructs the assembly was slow and
ine⁄cient. Moreover, the di⁄culty remained that
full-length tau would not assemble, and that native
PHFs contained both three-repeat and four-repeat
isoforms.
4.2. Polyanions stimulate PHF formation in vitro
A further important step was the observation that
several polyanionic cofactors greatly facilitate the
formation of PHFs from tau protein in vitro. These
polyanions can be heparin or other sulfated glycosa-
minoglycans [91,92], RNA [93] or polyglutamic acid
[92,94]. A role of these substances in PHF formation
is supported by the ¢nding that both sulfated glyco-
saminoglycans [95^97] and RNA [98,99] are found to
be associated with neuro¢brillary tangles. These poly-
anionic cofactors stimulate the assembly of full-
length tau, both with three and with four repeats,
within a few days. A systematic variation of the do-
main composition showed that all tau proteins would
assemble into PHFs provided that they contain at
least two repeats [93]. This emphasizes the role of
the repeat domain of tau in PHF assembly, consis-
tent with their presence in the cores of Alzheimer
PHFs. Secondly, the assembly still required disul¢de
cross-linking and could be prevented by reducing
agents such as dithiothreitol. Aggregation experi-
ments with small peptides in the presence of polyan-
ions (heparin or polyglutamic acid) comprising only
parts of the repeat region (the 18-amino acid residue
conserved part of the repeats) revealed that only pep-
tides from the third repeat and to a lesser extent
from the second repeat formed ¢bers, which, how-
ever, are much thinner and therefore do not resemble
PHFs [92,100]. An analysis of the in£uence of other
regions of the repeat on PHF formation awaits in-
vestigation.
In short, assembly of tau protein in oxidizing con-
ditions and in the presence of cytosolic nucleating
agents ful¢lls all the requirements for bona ¢de
PHF formation (full-length molecules, all isoforms).
This has opened the way for detailed studies of the
kinetic properties of PHF assembly, for analyzing
PHF assembly in cell models, and for studying the
structure of PHFs.
4.3. PHF formation is a nucleation-dependent process
The development of a quantitative assay for PHF
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formation using thio£avine S [94] which is known to
stain not only amyloid but also PHFs [65,80,101]
opened the way to a more detailed study of the
mechanism of PHF formation (Fig. 3). Using this
assay (with correlated electron microscopy to moni-
tor the morphology of the ¢laments), assembly stud-
ies revealed that even after formation of dimers and
in the presence of polyanions a kinetic barrier ex-
isted, which prevented the rapid formation of ¢la-
ments [91,94]. This suggested that a nucleation step
beyond dimerization is rate limiting. The slow nucle-
ation step, which requires an estimated number of
four to seven subunits ( = tau dimers) to form the
nucleus and therefore requires high concentration
of tau, could be circumvented and ¢lament forma-
tion drastically accelerated (to the range of minutes
to hours, depending of the tau construct used) by
adding small amounts of seeds [102]. These seeds
can be made either from authentic PHFs derived ex
vivo (isolated from the brains of AD patients) or
from ¢laments made in vitro from various tau con-
structs. Under such conditions even tau protein with-
out a cysteine residue (namely Cys322Ala), which
can only ine⁄ciently dimerize non-covalently, is
now able to form ¢laments in vitro, albeit at a
strongly reduced rate compared to the covalently
cross-linked variant. The need for stoichiometric
amounts of polyanions to achieve quantitative ¢la-
ment formation [91,92,94] is also observed under
seeding conditions. Thus even in the presence of
seeds dimeric tau will not readily assemble into ¢la-
ments without polyanions, which are therefore also
needed for elongation [102] (Fig. 4).
These features make PHF assembly broadly simi-
lar to amyloid ¢ber aggregation from AL in AD
[83,103], to Lewy body aggregation from K-synuclein
in Parkinson’s disease [104], to the aggregation of
huntingtin in Huntington’s disease [105] or to prion
protein aggregation in prion diseases [106]. Whether
heterologous nucleation (observed in amyloid forma-
tion) is also possible for tau is not known presently.
In summary, the best conditions for PHF formation
in vitro are (1) oxidative conditions to allow tau di-
merization, (2) presence of polyanions and (3) small
amounts of seeds.
4.4. PHF formation is retarded by phosphorylation
Since tau appears in the hyperphosphorylated
form in PHFs [75], it is commonly assumed that
this hyperphosphorylation of tau causes its detach-
ment from microtubules and promotes its assembly
into PHFs. However, in the absence of polyanions
full-length tau is not able to form ¢laments, and in
the presence of polyanions phosphorylated tau does
not aggregate faster than unmodi¢ed tau [107]. In a
systematic study using di¡erent kinases (MARK,
PKA, MAPK, GSK3) it was shown that phosphor-
ylation of tau by proline-directed kinases (MAPK
and GSK3, known to phosphorylate tau in the re-
gions adjacent to the repeat domain) had a weak
negative e¡ect on tau^microtubule interactions as
well as on PHF assembly [108]. By contrast, phos-
phorylation of tau by MARK and PKA (at the
KXGS motifs within the repeat region, especially
Ser262, and at Ser214 in the £anking region) strongly
inhibits tau’s attachment to microtubules. Signi¢-
cantly, this type of phosphorylation tends to inhibit
PHF formation, contrary to earlier expectations.
Therefore phosphorylation tends to protect tau
against PHF formation, rather than promoting it.
Fig. 3. Fluorescence assay of PHF assembly illustrating the ef-
fect of nucleation. Tau construct K19 was assembled in the
presence of poly-Glu and in the presence or absence of assem-
bly seeds obtained from pre-assembled PHFs and the extent of
polymerization was measured by ThS [94]. Bottom curve
(circles) : no seeds (spontaneous nucleation, note the lag phase).
Upper curves: increasing concentration of exogenous seeds
(seeded assembly, no lag phase). Adapted from [102].
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4.5. PHF formation and tau gene mutations
The ¢nding of mutations in the tau gene that cor-
relate with the development of disease with tau de-
posits raises the question of what role the mutations
play during tau ¢lament formation. Recent studies
with recombinant wild-type or mutant proteins as
found in disease (e.g. FTDP-17) suggest that some
but not all types of tau mutations lead to an accel-
erated ¢lament formation [100,109,110]. Therefore
the reason for disease development might in some
cases be directly related to the ¢lament formation
propensity of the proteins while in other cases an
altered function in tau^microtubule interaction might
be involved [73].
4.6. PHF formation and animal models
Using animal models (e.g. transgenic mice express-
ing mutant APP or presenilins) amyloid deposition is
Fig. 4. Diagram of tau dimerization, PHF nucleation and assembly. Tau monomers dimerize either covalently by oxidation (disul¢de
bridge formation, stable dimer) or non-covalently (unstable dimer). The dimer is the e¡ective building block of PHFs. Nucleation is
slow in the absence of polyanions but strongly accelerated in their presence (e.g. RNA, poly-Glu, heparin). Elongation (with or with-
out exogenous seeds) is slow in the absence of polyanions or by prevention of dimerization, indicating that a dimer^polyanion com-
plex is incorporated into PHFs. Excess of polyanion is inhibitory. Note that the stoichiometry and the arrangements are not known
and are only shown for illustration. Adapted from [102].
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observed while there is no evidence so far for neuro-
¢brillary pathology. Since subtle sequence changes
even in introns in the tau gene can in£uence the
function and result in disease (see FTDP-17) one
could also speculate that other variations could pre-
vent tau pathology. Using three- or four-repeat re-
combinant mouse tau it could be shown that at least
at the protein level there are no reasons why neuro-
¢brillary pathology is not observed in transgenic
mice. In vitro all mouse tau proteins could be aggre-
gated in the presence of polyanions in a way indis-
tinguishable from human tau [111]. Therefore the
absence of tau pathology in transgenic mice must
be explained by other yet unknown factors. Simple
overexpression of tau in transgenic animals also
failed to reveal neuro¢brillary pathology although
staining with certain disease-speci¢c antibodies has
been reported (e.g. 12E8 for phosphorylated
Ser262, AT-8 for Ser202/T205 [112^114]).
5. Future directions
A crucial question remains ^ how does the assem-
bly pathway outlined above pertain to neurons in
Alzheimer brain tissue? Cells normally have a reduc-
ing environment maintained by an excess of gluta-
thione. This ensures the successful scavenging of re-
active oxygen species and free radicals, and it
depends on a well-functioning energy metabolism.
AD appears early in large pyramidal neurons of
the hippocampus which have a high metabolic rate
and thus might be expected to be most vulnerable to
toxic e¡ects (e.g. glutamate excitotoxicity, toxic AL,
radicals generated by activated microglia, etc.). In
addition, mitochondrial DNA lacks the repair system
of nuclear DNA so that oxidative phosphorylation
becomes less e⁄cient with age, as seen from experi-
ments involving the mitochondria from Alzheimer
tissue [115]. The relative longevity of man may ex-
plain why other animals, including aged sheep or
monkeys [116] or transgenic mice overexpressing
the amyloid precursor protein [117] or human tau
[112], do not show neuro¢brillar pathology compa-
rable to that of AD.
Tau pathology is characteristic not only of AD but
also of several other neurodegenerative disorders.
Tau appears in aggregated ¢laments of varying mor-
phology, with di¡erent isoform composition and a
hyperphosphorylated form. The identi¢cation of the
tau gene as the genetic lesion in several hereditary
forms of dementias lends credence to the view that
tau ¢laments might be su⁄cient to cause nerve cell
degeneration. Recent advances in experimental in vi-
tro systems to study the aggregation of tau protein
into ¢laments have opened the way towards system-
atic studies of the mechanism of ¢lament formation
as well as the development of inhibitors of the pro-
cess. Although much progress towards the mecha-
nism of tau pathology has been made, several ques-
tions remain open and have to be addressed in the
future. (1) How do the parameters in£uencing tau
¢lament formation in vitro relate to the disease pro-
cess (i.e. oxidation, truncation, anionic cofactors)?
(2) What is the role of hyperphosphorylation and
other modi¢cations of tau during ¢lament forma-
tion? (3) What is the ¢rst nucleation step in the for-
mation of ¢laments in vivo? (4) Last but not least,
there is a need for an in vivo system (cell culture of
animal model) for tau pathology.
6. Note added in proof
We have recently found that a short hexapeptide
stretch at the beginning of the third repeat (306-VQI-
VYK-311) that induces PHF aggregation by forming
beta structure [118].
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